201
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 10, 2023Recruiting
Refractory Multiple Myeloma: 1456 Clinical Trials, Page 21 of 146
Hide Studies Not Open or Pending
202
Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple MyelomaLast Updated:February 7, 2013Completed
203
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 22, 2023Completed
204
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:June 2, 2016Unknown status
205
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple MyelomaLast Updated:October 11, 2013Completed
206
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Condition(s):Multiple Myeloma in Relapse; Multiple Myeloma, RefractoryLast Updated:May 9, 2022Recruiting
207
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 28, 2023Recruiting
208
UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):MULTIPLE MYELOMALast Updated:August 12, 2011Completed
209
Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:July 26, 2022Recruiting
210
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:December 28, 2022Active, not recruiting